Cargando…

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

Apixaban is a direct oral anticoagulant, a factor Xa inhibitor, used for the prevention of ischemic stroke in patients with atrial fibrillation. Despite using recommended dosing a few patients might still experience bleeding or lack of efficacy that might be related to inappropriate drug exposure. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Attelind, Sofia, Hallberg, Pär, Wadelius, Mia, Hamberg, Anna-Karin, Siegbahn, Agneta, Granger, Christopher B., Lopes, Renato D., Alexander, John H., Wallentin, Lars, Eriksson, Niclas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515473/ https://www.ncbi.nlm.nih.gov/pubmed/36186466 http://dx.doi.org/10.3389/fgene.2022.982955

Ejemplares similares

Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome
por: Johansson, Åsa, et al.
Publicado: (2015)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long‐term follow‐up of predictors, surveillance, and outcome in clinical practice
por: Karlsson Sundbaum, Johanna, et al.
Publicado: (2019)

HLA variants associated with azathioprine‐induced pancreatitis in patients with Crohn’s disease
por: Ås, Joel, et al.
Publicado: (2022)

Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2020)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children
por: Hamberg, Anna-Karin, et al.
Publicado: (2015)

Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials
por: Mahmoodi, Bakhtawar K., et al.
Publicado: (2021)

High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced Agranulocytosis
por: Cismaru, Anca Liliana, et al.
Publicado: (2020)

Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
por: Rao, Meena P., et al.
Publicado: (2015)

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
por: Pol, Tymon, et al.
Publicado: (2021)

Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
por: Mahmoodi, Bakhtawar K., et al.
Publicado: (2021)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Characterizing variability in warfarin dose requirements in children using modelling and simulation
por: Hamberg, Anna-Karin, et al.
Publicado: (2014)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Clinical factors predicting drug-induced liver injury due to flucloxacillin
por: Lindh, Mikaela, et al.
Publicado: (2018)

Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy
por: Rönnqvist, Josefine, et al.
Publicado: (2018)

Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival
por: Hallberg, Pär, et al.
Publicado: (2019)

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial
por: Hu, Peter T., et al.
Publicado: (2017)

Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21)
por: Siegbahn, Agneta, et al.
Publicado: (2023)

Apixaban: Gastrointestinal bleeding: case report
Publicado: (2021)

Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials
por: Hijazi, Ziad, et al.
Publicado: (2020)

Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
por: Jaspers Focks, Jeroen, et al.
Publicado: (2016)

SWEDEGENE—a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions
por: Hallberg, Pär, et al.
Publicado: (2020)

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
por: Pol, Tymon, et al.
Publicado: (2018)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
por: Halvorsen, Sigrun, et al.
Publicado: (2014)

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
por: Sandhu, Roopinder K, et al.
Publicado: (2018)

Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial
por: Guimarães, Patricia O., et al.
Publicado: (2019)

ADPKD, COVID-19, and Apixaban: The Treacherous Intracystic Bleeding − A Letter on Apixaban Causing Hepatic Cystic Bleeding by Shehi et al.
por: Sergi, Consolato M.
Publicado: (2022)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
por: Sattler, Laurent, et al.
Publicado: (2023)

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2020)

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
por: Pol, Tymon, et al.
Publicado: (2021)

Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2022)

Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
por: Benz, Alexander P, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vckot1dorllpka85esd2k5ungt